Table 1 Summary of age data per tumour-type.

Bladder Cancer

34–90 (69)

34–84 (65)

26–90.1 (67)

Breast Carcinoma

26–90 (59)

30–89 (56)

19–90.1 (55)

Biliary Cancer

–

37–84 (64)

24–85.1 (64)

Cervical Cancer

20–88 (46)

21–58 (39)

26–72 (48)

Colorectal Cancer

31–90 (68)

31–89 (67.5)

18–90.1 (56)

Glioblastoma

21–89 (62)

21–76 (59)

18–90.1 (60)

Medulloblastoma

–

18–49 (26)

28–72 (46)

Pilocytic Astrocytoma

–

20–50 (24)

29–44 (36.5)

Head and Neck Carcinoma

19–90 (61)

19–76 (53)

28–90.1 (59)

Clear Cell Renal Cell Carcinoma

26–90 (61)

38–84 (60)

31–85.1 (60)

Chromophobe Renal cell Carcinoma

26–86 (50)

28–86 (47.5)

30–73 (56)

Papillary Cell Renal Cell Carcinoma

28–88 (61)

–

36–77.1 (60)

Non-Hodgkin Lymphoma

–

18–85 (62)

29–84.1 (60)

Chronic Lymphocytic Leukaemia

–

40–86 (61)

44–72 (67)

Acute Myeloid Leukaemia

18–88 (58)

35–75 (50)

–

Myeloid-MPN

–

27–85 (54)

–

Lower Grade Glioma

18–87 (41)

21–62 (42)

21–81.1 (48)

Hepatocellular Carcinoma

18–90 (61)

23–89 (67)

18–90.1 (63)

Lung Adenocarcinoma

38–88 (67)

41–81 (65.5)

22–90.1 (68)

Lung Squamous Cell Carcinoma

40–85 (68)

47–83 (68)

30–90.1 (68)

Ovarian Cancer

26–89 (59)

39–81 (60)

26–84.1 (59)

Pancreatic Cancer

35–85 (66)

34–90 (67)

32–90.1 (67)

Pancreatic Endocrine Cancer

–

20–81 (59)

36–85.1 (58)

Pheochromocytoma

19–83 (46)

–

26–59 (41.5)

Prostate Cancer

41–78 (61)

38–80 (59)

43–90.1 (65)

Sarcoma

20–90 (60)

–

18–84.1 (52)

Melanoma

18–87 (55.5)

19–87 (57.5)

24–90.1 (64)

Stomach Adenocarcinoma

34–90 (67)

36–90 (65)

18–85.1 (59.5)

Esogapheal Carcinoma

27–90 (61)

44–87 (70)

18–88.1 (59)

Thyroid Cancer

18–89 (46)

18–85 (51)

22–88.1 (63)

Thymic Tumour

31–84 (61)

–

20–83.1 (59.5)

Endometrial Carcinoma

33–90 (63)

35–90 (69)

42–90.1 (60)

Pan-cancer

18–90 (60)

18–90 (62)

18–90.1 (60)